The global ablation devices market was valued at USD 6.13 Billion in 2024, driven by the increasing technological advancements across the globe. The market is anticipated to grow at a CAGR of 9.50% during the forecast period of 2025-2034, with the values likely to reach USD 15.19 Billion by 2034.
Ablation Devices Market Overview
Ablation devices are used to precisely remove or destroy abnormal tissue in the body, typically through minimally invasive procedures. The primary purpose is to treat conditions such as arrhythmias (irregular heartbeats), cancerous or benign tumors, chronic pain, and certain gynecological disorders. Ablation devices work by using energy sources such as radiofrequency, microwave, laser, or cryoablation to target and eliminate the problematic tissue without affecting surrounding healthy tissue. This approach can reduce the need for open surgery, lessen recovery time, and lower risks for patients by providing a targeted, controlled treatment option.
Ablation Devices Market Growth Drivers
FDA Approval of Johnson & Johnson's Varipulse System Drives Market Expansion
The rising prevalence of atrial fibrillation (AF) and the need for advanced, minimally invasive treatments are key drivers of the market. In November 2024, Johnson & Johnson MedTech received FDA approval for its Varipulse pulsed-field ablation (PFA) system, specifically for treating drug-resistant paroxysmal AF. The Varipulse system, integrated with Johnson & Johnson's Carto 3 electroanatomical mapping system, enables real-time procedural guidance and lesion tracking, enhancing procedural accuracy. This FDA approval, supported by positive results from the admIRE trial, reflects significant advancements in AF treatment technology. The Varipulse system is poised to impact market growth by offering a targeted, efficient solution for AF, likely accelerating the adoption of PFA systems during the forecast period.
Rising Innovations to Meet Rising Ablation Devices Market Demand
The increasing demand for efficient post-operative pain management and advancements in cryotherapy are key drivers for the global ablation devices market. In October 2024, AtriCure, Inc., launched its cryoSPHERE MAX cryoablation probe, a next-generation device designed to optimise Cryo Nerve Block therapy (cryoNB) for managing post-operative pain. This new probe features an enlarged ball tip, reducing freeze times by 50% compared to its predecessor, the cryoSPHERE cryoablation probe, and by over 30% compared to the cryoSPHERE®+ probe. AtriCure’s innovation in cryoablation technology addresses the need for faster, more efficient procedures, which is expected to drive market growth by expanding the clinical applications of cryoablation during the forecast period.
Ablation Devices Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technological Innovations Propel Ablation Devices Market Growth
The market is experiencing swift technological advancements, notably in pulsed-field and laser ablation systems that improve precision and safety. In October 2024, Abbott announced significant progress in expanding its pulsed field ablation (PFA) solutions in electrophysiology. Key milestones included the early completion of enrolment for the VOLT-AF IDE Study, supporting the Volt PFA System, and the launch of the FOCALFLEX trial, designed to assess the TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), for treating paroxysmal atrial fibrillation. These innovations address the growing demand for minimally invasive procedures, driving market growth by offering effective alternatives for complex cardiovascular and oncology treatments, with a dedicated emphasis on improving patient recovery and outcomes.
Rising FDA Approvals Fuel Market Expansion and Adoption
Rising FDA approvals for novel ablation technologies are driving significant market growth. In October 2024, Boston Scientific received FDA approval for its navigation-enabled ablation catheter for paroxysmal atrial fibrillation, along with 510(k) clearance for new imaging software for its pulsed-field ablation system. Following these approvals, the company immediately launched the ablation catheter (Farawave Nav) and imaging software (Faraview) commercially. These regulatory endorsements validate device safety and efficacy, allowing faster integration into healthcare settings. FDA support builds trust among providers and patients, accelerating the adoption and market reach of advanced ablation devices.
Market Shift Toward Minimally Invasive Treatments Drives Value
The growing shift toward minimally invasive procedures in healthcare is significantly boosting demand for ablation devices. These techniques, which offer faster recovery times, reduced complication risks, and cost savings, are highly appealing to both patients and providers. In July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, a cutting-edge device that enhances efficiency, control, and reliability for RF ablation procedures, offering lasting relief for those with facet joint pain. This trend is poised to increase market value, especially as advanced ablation solutions become increasingly available across various healthcare settings.
Emerging Markets Contribute Significantly to Global Market Development
Asia-Pacific and Latin America markets are becoming key contributors to global ablation device sales due to expanding healthcare infrastructure and increasing access to advanced technologies. With rising healthcare expenditure and a higher prevalence of treatable diseases, these regions present substantial growth opportunities, further driving global market development and enabling better patient outcomes.
Ablation Devices Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook